|By Business Wire||
|June 10, 2014 01:30 PM EDT||
Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Executive Chairman of its Board of Directors.
Hrusovsky brings more than twenty years of experience in life science and diagnostics industries. Prior to Quanterix, he was President of PerkinElmer Life Sciences & Technology; CEO of Caliper Life Sciences (sold to PerkinElmer for $650M); and CEO of Zymark Corporation (sold to Caliper for $150M). Earlier Hrusovsky was President of FMC Corporation’s Pharmaceuticals and International Agricultural Products and prior to that held numerous management positions at DuPont. He currently serves on the board of directors of SynapDx, 908 Devices and Solect Energy.
Hrusovsky received his B.S. in Mechanical Engineering from Ohio State University and M.B.A. from Ohio University. He was awarded the 2013 Entrepreneur of the Year from Ohio State University and holds an Honorary Doctorate degree from Framingham State University for contributions to life sciences and personalized medicine.
“I am very much compelled by the potential of Quanterix’ Simoa technology, the caliber of its board and leadership team and by the important opportunity to positively impact the world,” said Hrusovsky.
The appointment comes as Martin Madaus, formerly the Executive Chairman of the Board at Quanterix, is appointed Chairman and CEO of Ortho-Clinical Diagnostics (OCD) following the close of its acquisition from Johnson & Johnson by the Carlyle Group. Madaus will remain a member of Quanterix’ Board of Directors. “I couldn’t be more pleased that Kevin has accepted to become our new Executive Chairman at Quanterix,” said Madaus. “He is an outstanding leader with a strong track record for guiding innovative companies, creating value for shareholders and a great fit for Quanterix. Since the launch of the first Simoa products last year, the company has experienced rapid growth. Kevin’s leadership and experience will ensure the team at Quanterix has the support needed to continue that trajectory,” said Madaus.
To learn more about Simoa, please visit: www.quanterix.com.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.
Jul. 1, 2015 07:15 PM EDT Reads: 2,479
Jul. 1, 2015 05:00 PM EDT Reads: 769
Jul. 1, 2015 05:00 PM EDT Reads: 2,202
Jul. 1, 2015 04:09 PM EDT Reads: 458
Jul. 1, 2015 03:30 PM EDT Reads: 1,031
Jul. 1, 2015 03:00 PM EDT Reads: 1,918
Jul. 1, 2015 02:45 PM EDT Reads: 1,050
Jul. 1, 2015 02:30 PM EDT Reads: 1,173
Jul. 1, 2015 02:21 PM EDT Reads: 539
Jul. 1, 2015 01:15 PM EDT Reads: 2,149
Jul. 1, 2015 12:54 PM EDT Reads: 556
Jul. 1, 2015 12:15 PM EDT Reads: 2,044
Jul. 1, 2015 12:00 PM EDT Reads: 1,996
Jul. 1, 2015 11:45 AM EDT Reads: 1,012
Jul. 1, 2015 11:30 AM EDT Reads: 2,241